Posted by Michael Wonder on 07 Oct 2022
Hugel resubmits BLA for its botulinum toxin, Botulax to the US FDA
7 October 2022 - Hugel received CRL from the US FDA last March and completely supplemented documents and data.
Hugel announced that it resubmitted the BLA for its botulinum toxin called Botulax on 6 October, for the indication of glabellar lines to the US FDA.
